We conducted a quasi-experimental study to compare the response to meglumine
antimoniate in patients with localized cutaneous leishmaniasis from two endemic areas of …

Fundamentals: American tegumentary leishmaniasis (ATL) treatment remains a challenge,
since most available drugs are injectable and only a small number of comparative …

We retrospectively analyzed a series of 151 cases of cutaneous leishmaniasis treated
between 1967 and 1982. One-hundred-and-thirty-nine (92%) patients presented with active …

We investigated factors associated with treatment failure in the treatment of cutaneous
leishmaniasis with meglumine antimony in a reference service in Mato Grosso State. A …

Pentamidine was compared with meglumine antimoniate (Glucantime) for 80 patients with
cutaneous leishmaniasis due to Leishmania braziliensis in Peru. Of the 40 patients …

Clinical response to supervised treatment of Colombian patients with cutaneous
leishmaniasis was evaluated in a randomized controlled trial comparing 10 days versus 20 …

Background The drug of choice for leishmaniasis is pentavalent antimony and different
regimens are under continuous evaluation. The ideal therapy should be simple, effective …

Resistance of Leishmania parasites to specific chemotherapy has become a well‐
documented problem in the Indian subcontinent in recent years but only a few studies have …

Seventy-nine patients with cutaneous (62) or mucosal (17) infection with Leishmania
(Viannia) braziliensis in Três Braços, Bahia, Brazil, were followed for at least 4 years after …

Abstract Objectives Meglumine antimoniate (MA; Glucantime®), the 80‐year‐old first‐line
systemic treatment for all forms of American tegumentary leishmaniasis (ATL) caused by …